The interaction between physical activity and sleep on cognitive function and brain beta-amyloid in older adults.


Journal

Behavioural brain research
ISSN: 1872-7549
Titre abrégé: Behav Brain Res
Pays: Netherlands
ID NLM: 8004872

Informations de publication

Date de publication:
02 02 2023
Historique:
received: 03 06 2022
revised: 06 09 2022
accepted: 07 09 2022
pubmed: 14 9 2022
medline: 18 11 2022
entrez: 13 9 2022
Statut: ppublish

Résumé

Lifestyle factors such as physical activity and optimal sleep are associated with better cognition and lower levels of Alzheimer's disease (AD) biomarkers, including brain beta-amyloid (Aβ) burden. We utilised cross-sectional data from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study to determine whether self-reported physical activity (measured via the International Physical Activity Questionnaire) moderates the relationship between self-reported sleep (measured via the Pittsburgh Sleep Quality Index), cognition, and brain Aβ. Participants were 349 community-dwelling cognitively normal older adults (75.3 ± 5.7 years), all of whom underwent comprehensive cognitive assessment. Data from a subset of participants (n = 201) were used for analyses with brain Aβ burden (measured by positron emission tomography) as the outcome. Physical activity moderated the relationship between sleep duration and episodic memory (β = -0.10, SE =0.03, p = .005), and sleep efficiency and episodic memory (β = -0.09, SE =0.04, p = .011), such that greater amounts of physical activity mitigated the impact of suboptimal sleep duration and efficiency on episodic memory. Physical activity also moderated the relationship between sleep duration and brain Aβ (β = -0.13, SE =0.06, p = .031), and overall sleep quality and brain Aβ (β = 0.13, SE =0.06, p = .027). Our findings suggest that physical activity may play an important role in the relationship between sleep and cognitive function, and brain Aβ.

Sections du résumé

BACKGROUND
Lifestyle factors such as physical activity and optimal sleep are associated with better cognition and lower levels of Alzheimer's disease (AD) biomarkers, including brain beta-amyloid (Aβ) burden.
OBJECTIVE
We utilised cross-sectional data from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study to determine whether self-reported physical activity (measured via the International Physical Activity Questionnaire) moderates the relationship between self-reported sleep (measured via the Pittsburgh Sleep Quality Index), cognition, and brain Aβ.
METHODS
Participants were 349 community-dwelling cognitively normal older adults (75.3 ± 5.7 years), all of whom underwent comprehensive cognitive assessment. Data from a subset of participants (n = 201) were used for analyses with brain Aβ burden (measured by positron emission tomography) as the outcome.
RESULT
Physical activity moderated the relationship between sleep duration and episodic memory (β = -0.10, SE =0.03, p = .005), and sleep efficiency and episodic memory (β = -0.09, SE =0.04, p = .011), such that greater amounts of physical activity mitigated the impact of suboptimal sleep duration and efficiency on episodic memory. Physical activity also moderated the relationship between sleep duration and brain Aβ (β = -0.13, SE =0.06, p = .031), and overall sleep quality and brain Aβ (β = 0.13, SE =0.06, p = .027).
CONCLUSION
Our findings suggest that physical activity may play an important role in the relationship between sleep and cognitive function, and brain Aβ.

Identifiants

pubmed: 36100010
pii: S0166-4328(22)00376-X
doi: 10.1016/j.bbr.2022.114108
pii:
doi:

Substances chimiques

Amyloid beta-Peptides 0
Biomarkers 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

114108

Informations de copyright

Copyright © 2022 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Conflict of interest KRS, SRRS, JP, HRS, KT, DA, KIE and BMB report no disclosures. VLV is a consultant for IXICO and Life Molecular Imaging, and has received speaker honoraria from GE Healthcare, Piramal Lifesciences and Avid Radiopharmaceuticals. PM is a full-time employee of Cogstate Ltd. SML has previously been a paid consultant to Alzhyme. CLM is an advisor to Prana Biotechnology Ltd and a consultant to Eli Lilly. CCR has served on scientific advisory boards for Bayer Pharma, Elan Corporation, GE Healthcare and AstraZeneca, has received speaker honoraria from Bayer Pharma and GE Healthcare, and has received research support from Bayer Pharma, GE Healthcare, Piramal Lifesciences and Avid Radiopharmaceuticals. RNM is founder of, and owns stock in, Alzhyme, and is a co-founder of the KaRa Institute of Neurological Diseases.

Auteurs

Kelsey R Sewell (KR)

Centre for Healthy Ageing, Health Futures Institute, Murdoch University, Murdoch, Western Australia, Australia. Electronic address: Kelsey.sewell@murdoch.edu.au.

Stephanie R Rainey-Smith (SR)

Centre for Healthy Ageing, Health Futures Institute, Murdoch University, Murdoch, Western Australia, Australia; School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia, Australia; Australian Alzheimer's Research Foundation, Sarich Neuroscience Research Institute, Nedlands, Western Australia, Australia; School of Psychological Science, University of Western Australia, Perth, Western Australia, Australia.

Victor L Villemagne (VL)

School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia, Australia; Centre for Precision Health, Edith Cowan University, Joondalup, Western Australia, Australia; Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA; Department of Molecular Imaging & Therapy, Austin Health, Heidelberg, Victoria, Australia.

Jeremiah Peiffer (J)

Centre for Healthy Ageing, Health Futures Institute, Murdoch University, Murdoch, Western Australia, Australia.

Hamid R Sohrabi (HR)

Centre for Healthy Ageing, Health Futures Institute, Murdoch University, Murdoch, Western Australia, Australia; School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia, Australia; Australian Alzheimer's Research Foundation, Sarich Neuroscience Research Institute, Nedlands, Western Australia, Australia; Department of Biomedical Sciences, Macquarie University, Sydney, New South Wales, Australia.

Kevin Taddei (K)

School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia, Australia; Australian Alzheimer's Research Foundation, Sarich Neuroscience Research Institute, Nedlands, Western Australia, Australia.

David Ames (D)

Florey Institute of Neuroscience and Mental Health, Parkville, Victoria, Australia; National Ageing Research Institute, Parkville, Victoria, Australia; University of Melbourne Academic Unit for Psychiatry of Old Age, St George's Hospital, Kew, Victoria, Australia.

Vincent Doré (V)

Department of Molecular Imaging & Therapy, Austin Health, Heidelberg, Victoria, Australia.

Paul Maruff (P)

Florey Institute of Neuroscience and Mental Health, Parkville, Victoria, Australia; Cogstate Ltd, Melbourne, Victoria, Australia.

Simon M Laws (SM)

Centre for Precision Health, Edith Cowan University, Joondalup, Western Australia, Australia; Collaborative Genomics and Translation Group, School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia, Australia; School of Pharmacy and Biomedical Sciences, Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University, Bentley, Western Australia, Australia.

Colin L Masters (CL)

Florey Institute of Neuroscience and Mental Health, Parkville, Victoria, Australia.

Christopher C Rowe (CC)

Department of Molecular Imaging & Therapy, Austin Health, Heidelberg, Victoria, Australia; Florey Institute of Neuroscience and Mental Health, Parkville, Victoria, Australia.

Ralph N Martins (RN)

School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia, Australia; Australian Alzheimer's Research Foundation, Sarich Neuroscience Research Institute, Nedlands, Western Australia, Australia; Department of Biomedical Sciences, Macquarie University, Sydney, New South Wales, Australia.

Kirk I Erickson (KI)

Department of Psychology, University of Pittsburgh, Pittsburgh, PA, USA.

Belinda M Brown (BM)

Centre for Healthy Ageing, Health Futures Institute, Murdoch University, Murdoch, Western Australia, Australia; School of Medical and Health Sciences, Edith Cowan University, Joondalup, Western Australia, Australia; Australian Alzheimer's Research Foundation, Sarich Neuroscience Research Institute, Nedlands, Western Australia, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH